ClinicalTrials.gg
RecruitingNCT05176665Updated Aug 26, 2024

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

A Phase 1/2 interventional study of EMB-01 in Neoplasms, Neoplasm Metastasis and Metastatic Gastrointestinal Carcinoid Tumor, sponsored by Shanghai EpimAb Biotherapeutics Co., Ltd.. Recruiting at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-26.

Primary conditionNeoplasm MetastasisRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neoplasm Metastasis
Why
  1. The study's listed conditions name Neoplasm Metastasis, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shanghai EpimAb Biotherapeutics Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
152
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 485 studies in Neoplasm Metastasis with a site in China — 222 open to participants now, 263 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Planned enrollment
149th of 401
152 · median 90
Started
2021
with 47 others
Phase 1/2
48 of 485
23 open now
Primary completion
2025-12
later than 53 of 262 live
Registered
209th of 485
by date

Among the 485 studies in Neoplasm Metastasis with a site in China, this one is the 149th largest by planned enrollment of the 401 interventional ones that give a count, is one of 48 that started in 2021, is one of 48 in phase 1/2, reaches primary completion later than 53 of the 262 other live ones, and was the 209th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

222 of the 485 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

217 more — sign in →

All 222 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 485 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.

Read the detailed description

This is an open-label, Phase Ib/II, multi-stage study of EMB-01 in patients with advanced gastrointestinal tumors including gastric cancer, hepatocellular cancer, cholangiocarcinoma cancer and colorectal cancer, who have EGFR/cMET gene alterations or protein over expression and progressed on available standard therapies and for whom no standard therapy exists that would confer clinical benefit. All patients will be prescreened for cMET and EGFR genetic alterations and protein expression. Only those who met the molecular pre-screening criteria will proceed to clinical screening to determine the eligibility. The study will consist of Phase Ib part and Phase II part, both phases will consist of a molecular prescreening period, screening period, treatment period, safety follow-up period, and disease progression follow-up.

03

Conditions studied

  • Neoplasms
  • Neoplasm Metastasis
  • Metastatic Gastrointestinal Carcinoid Tumor

Browse trials for

Keywords

  • Human Bispecific antibody
  • Epidermal Growth Factor Receptor (EGFR)
  • c-Mesenchymal-Epithelial Transition (cMet)
  • Neoplasms, Neoplasm Metastasis
  • Neoplasm Metastasis
  • EMB-01,Tyrosine Kinase Inhibitor (TKI) Resistant
04

In context

Neoplasm Metastasis Reclassified

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

This study's planned enrollment of 152 is above the median of 50 across 3,271 interventional studies indexed under Neoplasm Metastasis.

Browse Neoplasm Metastasis studies →

Lead sponsor

Shanghai EpimAb Biotherapeutics Co., Ltd. is the lead sponsor of 10 studies on the registry; 8 are open to participants now.

Compared within Neoplasm Metastasis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Molecular Pre-screening Inclusion criteria

  1. cMET amplification in tumor sample; OR
  2. cMET overexpression in tumor sample; OR
  3. EGFR overexpression in tumor sample; OR
  4. Other EGFR or cMET gene alteration in blood sample (circulating tumor DNA, ctDNA).

In Phase II, CRC patients must provide blood sample for NGS test, but may not provide tumor samples at prescreening visit. CRC patients don't need to meet the above criteria of EGFR/cMET amplification, overexpression or gene aberration.

Screening Inclusion Criteria

  1. Able to understand and willing to sign the Form (ICF).
  2. Histologically/ confirmed advanced/ gastric cancer, HCC, BTC, and colorectal cancer with ( V1.1). To be eligible, patients must meet following criteria:

    1. Have failed all standard of care therapies known to confer clinical benefit. Patients who is not tolerable on standard of care therapies, or no standard of care therapies available, or refused standard of care therapies are eligible.
    2. Have measurable disease as defined by RESIST v 1.1.
  3. (formalin-fixed or paraffin-embedded, collected within 1 year) or a new biopsy collected in the molecular pre-screening visit.
  4. Must have adequate organ function.
  5. Regarding prior anti-tumor therapy:

    1. Patients who have received any anticancer drugs approved or , including chemotherapy, immune therapy, hormonal therapy (Exceptions: hormone-replacement therapy, testosterone or oral ), biologic therapy, must have stopped treatment at least 4 weeks or within 5 half -lives whichever shorter before first dose of EMB-01.
    2. Local radiotherapy or radiation therapy for bone metastases must have stopped 2 weeks before first dose of EMB-01. No therapeutic radiopharmaceuticals are taken within 8 weeks before first dose of EMB-01.
    3. Patients who have received prior targeted therapies must have stopped treatment for at least 4 weeks or within 5 half-lives, whichever is shorter before first dose of EMB-01.
  6. Female patient with fertility or male patient whose partner has fertility should use one or more contraceptive methods for contraception starting from screening period and continue throughout the study treatment and for 3 months.
  7. score ≤1.

Exclusion criteria

Exclusion Criteria:

Molecular Pre-screening Exclusion Criteria

Subject who meets any of the following criteria can't be proceeded to clinical screening:

  1. Patients who are unwilling to sign the molecular pre-screening ICF.
  2. Patients for whom the results of central laboratory testing do not meet the molecular pre-screening inclusion criteria.
  3. Patients with a documented gene alteration including but not limited to , KRAS, NRAS, BRAF, NTRK, ALK, RET, ROS1, and FGFR, etc. that is known to confer resistance to EGFR and/or cMET inhibitors.* * In Phase II, CRC patients with activated KRAS, NRAS or BRAF mutation should be excluded, but patients with other gene alterations do not need to be excluded.

Screening Exclusion Criteria

  1. \< 3 months.
  2. Patients with primary central nervous system (CNS) or symptomatic CNS ( or brain) are not allowed. Patients with asymptomatic are eligible.
  3. Pregnant or nursing females.
  4. Patients who have had major surgery within the 28 days from the screening. Surgical wounds must be completely healed.
  5. Any other serious underlying medical (e.g. uncontrolled diabetes mellitus, active uncontrolled infection, active gastric ulcer, uncontrolled seizures, cerebrovascular incidents, gastrointestinal bleeding, severe signs and symptoms of coagulation and clotting disorders, cardiac conditions), psychiatric, psychological, familial or geographical condition that, in the judgment of the investigator, may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
152 participants (estimated)

Study arms

  • Experimental
    Phase Ib and Phase II

    The study will consist of Phase Ib and Phase II. The study is planning to recruit approximately 152 patients in total for advanced/metastatic GI cancers, which include 24 patients in Phase Ib and up to approximately 128 patients in Phase II. For GC, HCC, and BTC groups, up to approximately 24 patients may be enrolled in Phase Ib and Phase II. For CRC group, up to approximately 80 patients may be enrolled in Phase Ib and Phase II with up to 40 patients in each subgroup.

    Drug: EMB-01

Interventions

  • DrugEMB-01

    EMB-01 at the RP2D of 1600 mg will be administered as an IV infusion once weekly (QW) throughout the study. One cycle is defined as 4 weeks (4 doses).

    Also known as: FIT-013a

07

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events and Serious Adverse Events as assessed by CTCAE v5.0

    Number of participants with Adverse Events and Serious Adverse Events as assessed by CTCAE v5.0

    Time frame: Phase 1b, screening up to follow-up (30 days after the last dose)

  2. Best Overall Response (BOR) as assessed by RECIST v1.1

    Best Overall Response (BOR) as assessed by RECIST v1.1

    Time frame: Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

  3. Objective Response Rate (ORR) as assessed by RECIST v1.1

    Objective Response Rate (ORR) as assessed by RECIST v1.1

    Time frame: Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

  4. Duration of Response (DoR) as assess by RECIST v1.1 as assess by RECIST v1.1

    Duration of Response (DoR) as assess by RECIST v1.1 as assess by RECIST v1.1

    Time frame: Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

  5. Disease Control Rate (DCR) as assess by RECIST v1.1

    Disease Control Rate (DCR) as assess by RECIST v1.1

    Time frame: Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

  6. Progression-Free Survival (PFS) as assess by RECIST v1.1

    Progression-Free Survival (PFS) as assess by RECIST v1.1

    Time frame: Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

  7. Maximum serum concentration (Cmax) of EMB-01

    Maximum serum concentration (Cmax) of EMB-01

    Time frame: Phase Ib only, up to 3 months after first study drug administration

  8. Trough serum concentration (Ctrough) of EMB-01

    Trough serum concentration (Ctrough) of EMB-01

    Time frame: Phase Ib only, predose, through treatment completion, an average of 1 year

  9. Area under the concentration-time curve from time 0 (pre-dose) to the time of the dosing interval (AUC0-t)

    Area under the concentration-time curve from time 0 (pre-dose) to the time of the dosing interval (AUC0-t)

    Time frame: Phase Ib only, up to 3 months after first study drug administration

  10. Area under the concentration-time curve from time 0 to infinity (AUC0-inf)

    Area under the concentration-time curve from time 0 to infinity (AUC0-inf)

    Time frame: Phase Ib only, up to 3 months after first study drug administration

  11. Elimination half-life (T1/2)

    Elimination half-life (T1/2)

    Time frame: Phase Ib only, up to 3 months after first study drug administration

  12. Systemic clearance (CL)

    Systemic clearance (CL)

    Time frame: Phase Ib only, up to 3 months after first study drug administration

  13. Apparent volume of distribution at steady-state (Vss)

    Apparent volume of distribution at steady-state (Vss)

    Time frame: Phase Ib only, up to 3 months after first study drug administration

  14. Accumulation Ratio (AR) after multiple dosing

    Accumulation Ratio (AR) after multiple dosing

    Time frame: Phase Ib only, up to 3 months after first study drug administration

  15. Incidence of positive ADA

    Incidence of positive ADA

    Time frame: Phase Ib only, up to the 30-day safety follow-up visit after EOT

  16. Clinical benefit rate(CBR) as assess by RECIST v1.1

    Clinical benefit rate(CBR) as assess by RECIST v1.1

    Time frame: Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

Secondary outcomes

  1. Number of participants with Adverse Events and Serious Adverse Events as assessed by CTCAE v5.0

    Number of participants with Adverse Events and Serious Adverse Events as assessed by CTCAE v5.0

    Time frame: Phase II, screening up to follow-up (30 days after the last dose)

  2. Maximum serum concentration (Cmax) of EMB-01

    Maximum serum concentration (Cmax) of EMB-01

    Time frame: Phase II, up to 3 months after first study drug administration

  3. Trough serum concentration (Ctrough) of EMB-01

    Trough serum concentration (Ctrough) of EMB-01

    Time frame: Phase II, predose, through treatment completion, an average of 1 year

  4. Incidence of positive ADA

    Incidence of positive ADA

    Time frame: Phase II , up to the 30-day safety follow-up visit after EOT

  5. Best Overall Response (BOR) as assessed by RECIST v1.1

    Best Overall Response (BOR) as assessed by RECIST v1.1

    Time frame: Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

  6. Objective Response Rate (ORR) as assessed by RECIST v1.1

    Objective Response Rate (ORR) as assessed by RECIST v1.1

    Time frame: Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

  7. Duration of Response (DoR) as assess by RECIST v1.1 as assess by RECIST v1.1

    Duration of Response (DoR) as assess by RECIST v1.1 as assess by RECIST v1.1

    Time frame: Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

  8. Disease Control Rate (DCR) as assess by RECIST v1.1

    Disease Control Rate (DCR) as assess by RECIST v1.1

    Time frame: Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

  9. Progression-Free Survival (PFS) as assess by RECIST v1.1

    Progression-Free Survival (PFS) as assess by RECIST v1.1

    Time frame: Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

  10. Clinical benefit rate(CBR) as assess by RECIST v1.1

    Clinical benefit rate(CBR) as assess by RECIST v1.1

    Time frame: Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

08

Study locations

12 of 14 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Dec 2025, 50 months after the start.

Of 127 industry-sponsored phase 1/2 interventional studies under Neoplasm Metastasis, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 89. This study's planned 50 months is below that.

Counting every sponsor, half of 213 studies reached it within 62 months; a quarter within 41 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2021
First posted
Jan 4, 2022
StartActual
Oct 21, 2021
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Aug 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05176665
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Collaborators
Labcorp Corporation of America Holdings, Inc
Responsible party
Sponsor
First posted
Jan 4, 2022
Start date
Oct 21, 2021
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Aug 26, 2024

Study contacts

Rong Wang, M.Sc
Contact
CT.info@epimab.com
+86-21-61043299
Di Hu, M.Sc
Contact
CT.info@epimab.com
+862161043299

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bafisontamab

Start the discussion